Lexion Medical, LLC v. Surgiquest, Inc.

8 F. Supp. 3d 1122, 2014 U.S. Dist. LEXIS 39770, 2014 WL 1260761
CourtDistrict Court, D. Minnesota
DecidedMarch 26, 2014
DocketCiv. No. 13-2453 (RHK/FLN)
StatusPublished
Cited by2 cases

This text of 8 F. Supp. 3d 1122 (Lexion Medical, LLC v. Surgiquest, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lexion Medical, LLC v. Surgiquest, Inc., 8 F. Supp. 3d 1122, 2014 U.S. Dist. LEXIS 39770, 2014 WL 1260761 (mnd 2014).

Opinion

MEMORANDUM OPINION AND ORDER

RICHARD H. KYLE, District Judge.

INTRODUCTION

Plaintiff Lexion Medical, LLC (“Lex-ion”) and Defendant SurgiQuest, Inc. (“SurgiQuest”) manufacture and sell in-sufflation devices used in laparoscopic surgery.1 Lexion commenced the instant action against SurgiQuest in September 2013, alleging that SurgiQuest had made false representations while advertising and marketing its insufflation device. Presently before the Court is SurgiQuest’s Motion to Dismiss for lack of personal jurisdiction or, in the alternative, for partial dismissal for failure to state a claim. For the reasons that follow, the Motion will be granted in part and this action dismissed without prejudice for lack of personal jurisdiction.

BACKGROUND

I. The parties and their devices

Lexion is a Delaware company headquartered in St. Paul, Minnesota. (Am. [1125]*1125Compl. ¶ 1.) It manufactures and sells the “Insuflow” device used in laparoscopic surgery, which it sells to surgeons and hospitals throughout the United States, including in Minnesota. (Id. ¶¶ 5, 9.) The device employs a one-way valve to prevent insuff-lation gas from escaping during surgery. But the gas leaks when, for example, instruments are passed through the valve, and hence more and more carbon dioxide, which is both cold and dry, must be pumped into the patient during a procedure. (Dugan Decl. ¶ 3.) Lexion’s device warms and humidifies this gas as it enters the surgical cavity, which it claims is “scientifically proven to be the only method for reducing the side effects” of gas use during laparoscopic surgery. (Am. Compl. ¶ 8.)

SurgiQuest is a Delaware corporation headquartered in Connecticut. (Id. ¶ 2.) It manufactures and sells the “AirSeal” device used in laparoscopic surgery, which works differently than Lexion’s Insuflow device. (Id. ¶ 11.) SurgiQuest’s device is valveless and utilizes “a horizontal air barrier” to prevent insufflation gas from escaping. (Dugan Decl. ¶ 5.) As a result, it “constantly re-circulates and filters the original [insufflation] gas, without the need to introduce large amounts of additional gas.” (Id.) Heating and humidifying is not required when using the AirSeal device, according to SurgiQuest, because the device “does not cause meaningful cooling or drying of the [surgical] environment,” as it does not permit insufflation gas to escape and, hence, additional cold, dry gas need not be pumped into the patient. (Id. ¶¶ 3, 5.)

II. The instant litigation

Lexion commenced this action against SurgiQuest on September 6, 2013. It alleges that SurgiQuest’s marketing materials “falsely state its AirSeal [device] is capable of reducing the side effects linked to the use of unconditioned insufflation gas” and that “it is unnecessary to warm and humidify the insufflation gas to reduce side effects.” (Am. Compl. ¶¶ 13-14.) It further alleges that SurgiQuest’s employees repeated these “misrepresentations” in sales meetings held throughout the United States, including in Minnesota. (Id. ¶¶ 15-16.) And it claims that due to these “misrepresentations,” doctors and others were influenced to purchase the AirSeal device, which has caused it (Lexion) to lose sales to prospective customers. (Id. ¶¶ 18-21.) This conduct, according to Lexion, constituted false advertising in violation of the Lanham Act, 15 U.S.C. § 1051 et seq., and deceptive and unlawful trade practices under Minnesota law.

III. SurgiQuest’s Minnesota contacts

SurgiQuest has no physical presence in Minnesota. (Dugan Decl. ¶ 8.) It owns no property here, has no offices here, and does not manufacture products here. (Id.) It is not registered to do business in Minnesota and has never been subject to Minnesota income taxes. (Id. ¶ 7.) It does not direct, and has never directed, any advertisements of any kind regarding its AirSeal device or any other product to Minnesota. (Id. ¶¶ 9, 12.) Instead, Surgi-Quest’s Minnesota contacts are primarily limited to the following:

First, in 2012, surgeons at Mercy Hospital (“Mercy”) in Coon Rapids, Minnesota, heard about the AirSeal device and wanted to learn more about it. (Dooher Decl. ¶ 3.) Mercy set up a meeting in Minnesota with two SurgiQuest employees, who provided additional information about the device. Mercy then obtained an AirSeal device and evaluated it in surgeries in October and November 2012. That eventually led Mercy to decide to purchase the device in March 2013, at a cost of approximately [1126]*1126$25,000. (Id. ¶¶ 4-5; Dugan Decl. ¶ 16.) This constitutes the only AirSeal device SurgiQuest has sold in Minnesota. (Du-gan Decl. ¶ 14.) Second, the AirSeal device uses “consumables,” such as filters and other disposable items, which must be replaced regularly. Mercy has sent more than 80 purchase orders to SurgiQuest for such items, often more than once per week, for total sales of nearly $60,000 since it began using the AirSeal device. (Gleek-el Decl. Ex. 3.) Third, one of SurgiQuest’s employees lives in Minnesota, although he works out of an office in Connecticut; as a result, SurgiQuest pays unemployment taxes to the state of Minnesota. (Dugan Decl. ¶ 7.)

IV. The present Motion

SurgiQuest moved to dismiss this case in October 2013, arguing that personal jurisdiction is lacking in Minnesota. Lexion responded with an Amended Complaint amplifying its allegations and citing the sale to Mercy, of which it learned via early discovery, as a Minnesota contact. Surgi-Quest now moves to dismiss the Amended Complaint for lack of personal jurisdiction or, alternatively, to dismiss Lexion’s state-law causes of action for failure to state a claim. The Motion has been fully briefed, the Court heard argument on March 11, 2014, and the Motion is ripe for disposition.

STANDARD OF REVIEW2

In order to survive SurgiQuest’s Motion, Lexion must make only a prima facie showing of jurisdiction. E.g., Epps v. Stewart Info. Servs. Corp., 327 F.3d 642, 647 (8th Cir.2003). This requires it to proffer “sufficient facts ... to support a reasonable inference that [SurgiQuest] can be subjected to jurisdiction within [Minnesota].” Dairy Farmers of Am., Inc. v. Bassett & Walker Int’l, Inc., 702 F.3d 472, 475 (8th Cir.2012) (citations omitted). Because SurgiQuest controverts the existence of jurisdiction, Lexion’s showing “must be tested[ ] not by the pleadings alone, but by the affidavits and exhibits presented with the motion[] and in opposition thereto.” Id. (citations omitted). And where, as here, the Court does not hold an evidentia-ry hearing, it must “look at the facts in the light most favorable to the nonmoving party, and resolve all factual conflicts in favor of that party.” Pangaea, Inc. v. Flying Burrito LLC, 647 F.3d 741, 745 (8th Cir.2011) (citation omitted).

ANALYSIS

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Aronson v. Celebrity Cruises, Inc.
30 F. Supp. 3d 1379 (S.D. Florida, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
8 F. Supp. 3d 1122, 2014 U.S. Dist. LEXIS 39770, 2014 WL 1260761, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lexion-medical-llc-v-surgiquest-inc-mnd-2014.